BioSpace News Archive

ResMed announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wide variety of out-of-hospital care providers.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced today that it will present a corporate overview at the RHK 2022 Disruptive Growth Conference being held December 5-6, 2022, at the offices of Reed Smith in New York City.

Subtle Medical, a leading healthcare technology provider, announced it will be showcasing its award winning AI-powered software solutions, SubtleMR™ and SubtlePET™, along with a robust pipeline of new products in research and development, at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).

2023 Revenue Covenant tied to percentage of Company’s annual operating plan and substantially waived if Company raises $15 million of new funding.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical company developing novel therapies for women’s health, today announced the sale of all of the Company’s rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million and future milestone payments of up to $98 million.